The most useful starting point for LL-37 wound-healing claims is the later trial’s overall result: it did not show a significant healing improvement across the full study population. Earlier signals and a later subgroup observation remain scientifically interesting, but neither should replace that finding. The studies concern topical treatment for hard-to-heal venous leg ulcers, a specific wound population.
The early trial generated a hypothesis
The 34-participant early randomized trial investigated topical LL-37 over a four-week treatment phase after a run-in. Some lower-concentration groups showed improved healing predictors, while the highest-concentration group did not differ from placebo. Small groups and dose exploration make this a signal-generating study. Its positive title should be read together with the actual design, measurements and later research.
A healing predictor is not automatically the same outcome as complete wound closure. Wound-area change, healing rate and the proportion fully healed answer related but different questions. When comparing a claim with the paper, identify which measurement the authors actually reported and when it was assessed. Otherwise, a change in a predictor can gradually become an unsupported claim that the treatment reliably closes wounds.
HEAL LL-37 tested a larger population
HEAL LL-37 randomized 149 participants to topical LL-37 or placebo alongside compression. Of these, 148 received treatment and entered the safety set, and 144 entered the full analysis set for efficacy. The full-cohort efficacy analysis found no significant healing improvement. A post hoc analysis suggested benefit among people with larger target wounds; the authors called for an adequately powered follow-up study. That subgroup observation does not establish general effectiveness or a prospectively validated rule for selecting patients.
Why the subgroup does not replace the main result
A subgroup analysis asks what happened within part of the sample. When the subgroup is examined after the overall data are available, it can help formulate the next experiment. It is less convincing as confirmation of a treatment-selection rule than a study designed in advance to test that rule. The distinction should remain visible even if the subgroup result is statistically significant.
For a reader, the practical question is whether the proposed benefit has been independently confirmed in the specified population. An appealing explanation for why a subgroup might respond is not that confirmation. Nor is the claim strengthened by showing only the favorable subgroup in a graphic while omitting the negative overall result.
Keep the treatment setting attached
| Study detail | Boundary for interpretation |
|---|---|
| Venous leg ulcers | Does not establish benefit for every wound or injury. |
| Topical preparation | Does not establish injected LL-37 effectiveness. |
| Compression background care | Does not test replacing the surrounding wound-care plan. |
| Healing measurements | Does not establish infection eradication or systemic immune enhancement. |
A useful discussion with a wound clinician
Ask which wound diagnosis is being treated, which outcome needs improvement and which established care is already in place. If an LL-37 paper is presented as relevant, ask how its population, formulation and background care match the proposal. Bring both the early trial and HEAL LL-37 rather than a single favorable quotation.
These studies justify continued research and careful reporting. They do not justify a broad promise that LL-37 heals wounds. A clear evidence summary can acknowledge the early signal, state the negative whole-cohort finding and explain what future confirmation would need to show, without turning uncertainty into a product offer.
Sources and reading scope
- Topical LL-37 in hard-to-heal venous leg ulcers: early randomized trial
- HEAL LL-37: phase IIb randomized placebo-controlled venous-ulcer trial
- HEAL LL-37 full paper: participant flow and analysis populations
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.